ArticleWorld journal of gastroenterology2003
Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?
Article in World journal of gastroenterology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up.World journal of gastroenterology · 2011Trial
- Metallophosphoesterase 1, a novel candidate gene in hepatocellular carcinoma malignancy and recurrence.Cancer biology & therapy · 2020Article
- Hepatocellular carcinoma: radiomics nomogram on gadoxetic acid-enhanced MR imaging for early postoperative recurrence prediction.Cancer imaging : the official publication of the International Cancer Imaging Society · 2019Article
- Prognostic value ofOncoTargets and therapy · 2016Article
- Article
- Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population.Digestive diseases and sciences · 2013Article
- Protein kinases and transcription factors activation in response to UV-radiation of skin: implications for carcinogenesis.International journal of molecular sciences · 2012Review
- Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan.Hepatology international · 2011Article
- Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?Cell & bioscience · 2011Article
- Molecular genetics of hepatocellular neoplasia.American journal of translational research · 2010Article
- Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCV-related Hepatocellular Carcinoma Cases in Egypt.International journal of health sciences · 2008Article
- Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.Journal of cancer research and clinical oncology · 2004Review
- Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells.World journal of gastroenterology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate mutant p53 gene in primary hepatocellular carcinoma and to investigate the correlation between it and the recurrence of hepatocellular carcinoma.
methodsMutations of p53 gene were examined using anti-human p53 monoclonal antibody and immunohistochemical staining in 79 resected hepatocellular carcinomas. The correlations among variables of p53 positivity and invasiveness, disease free interval and survival were studied. In addition, in those who developed recurrence, the correlation among p53 positivity, clinical features and post-recurrence survival were also studied.
resultsOf these 79 cases, 64 (81 %) had p53 mutation. Those patients with mutant p53 positivity had significantly more tumor recurrence (76.6 % vs 40.0 %, P=0.0107). However, the COX proportional hazards model showed that p53 overexpression had only weak correlations with recurrence free interval and survival time (P=0.088 and 0.081), which was probably related to the short duration of follow-up. The invasiveness variables may be predictors of HCC recurrence. On univariate analysis, more patients with mutant p53 positivity had vascular permeation (78.1 vs 40.0 %, P=0.0088, O.R. (odds ratio) =5.3), grade II-IV differentiation (98.4 vs 80.0 %, P=0.0203, O.R. =15.7), no complete capsule (82.8 vs 53.3 %, P=0.0346, O.R. =4.2) and daughter nodules (60.9 vs. 33.3 %, P=0.0527, O.R. =3.1) than patients with negative p53 staining. On multivariate analysis, only vascular permeation and grade of differentiation remained significant (P=0.042 and 0.012). There was no statistically significant correlation between the status of p53 in the primary lesion and the clinical features of recurrent hepatocellular carcinomas examined, including extrahepatic metastasis (P=0.1103) and the number of recurrent tumors (P=1.000) except for disease over more than one segment in the extent of recurrent tumors (P=0.0043). The post-recurrence median survival was lower in patients in whom p53 mutation had been detected in the primary lesion with a weak significance (3.42 months vs 11.0 months, P=0.051).
conclusionOur findings suggest that p53 mutation correlates significantly with invasiveness including vascular permeation, grade of cellular differentiation, incomplete capsule and multinodular lesions. Hepatocellular carcinomas with p53 mutations had more tumor recurrence and p53 mutation may also influence disease recurrence interval and survival time. Hepatocellular carcinomas with p53 mutations recur more extensively with a shorter survival. Therefore, p53 mutation in the primary lesion is useful as an indicator of the biological behavior of recurrent hepatocellular carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.